Clinical Trial: ALLIANCE A012103

ALLIANCE A012103

Status: Open

NCT#05812807

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Eligible for screening study DCP 001

Completion of Pre-Registration QOLs is required after consent, prior to registration. Please see study documents.

A012103 is closed to accrual to HO1 Quality of Life Sub Study, effective July 15, 2025.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Available Clinical Trials

Clinical Trial: ALLIANCE A012103

ALLIANCE A012103

NCT#05812807

Navigation

About Us

Contact Us